EyePoint Completes Enrollment
EyePoint completes phase 3 trials
Story updates
11:01:35 AM UTC
SquawkNews
EYPT Eyepoint completes enrollment of both pivotal phase 3 trials of duravyu™ for treatment of diabetic macular edema (dme) Eyepoint - topline data for dme phase 3 trials anticipated in Q4 2027 - Phase 3 wet amd program data anticipated beginning August 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.